2018 Gastroesophageal Reflux Disease (GERD) Drug Development Pipeline Analysis Report - ResearchAndMarkets.com

DUBLIN--()--The "2018 Gastroesophageal Reflux Disease (GERD) Drug Development- Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering.

With an estimated 25 million people being affected by Gastroesophageal reflux disease (GERD) in the US, it is considered as one of the most common GI Disorders. GERD causes stomach contents regurgitate into the esophagus, causing damage to esophagus.

Around 30 companies and universities are focusing on developing treatment options for Gastroesophageal Reflux Disease (GERD).

To assist investigators and funding and regulatory organizations, the publisher has come up with a comprehensive report on Gastroesophageal Reflux Disease (GERD) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Gastroesophageal Reflux Disease (GERD) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Gastroesophageal Reflux Disease (GERD) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Key Topics Covered:

1 Figures & Tables

2 Gastroesophageal Reflux Disease (GERD) Pipeline Analysis

2.1 Disease and Pipeline Overview

2.2 Gastroesophageal Reflux Disease (GERD) Pipeline Snapshot

2.3 Gastroesophageal Reflux Disease (GERD) Pipeline by Phase

2.4 Gastroesophageal Reflux Disease (GERD) Pipeline by Company

2.5 Gastroesophageal Reflux Disease (GERD) Pipeline by Mechanism of Action

3 Gastroesophageal Reflux Disease (GERD)- Company Wise Pipeline Analysis

  • Cancer Advances Inc
  • CJ HealthCare
  • Daewoong Pharmaceutical Co
  • Effexus Pharmaceutical
  • Eisai Co Ltd
  • Il-Yang Pharm.Co.,Ltd
  • Ironwood Pharmaceuticals
  • Jeil Pharmaceutical Co Ltd
  • Jiangsu Aosaikang Pharmaceutical
  • Mitsubishi Pharma Corporation
  • New Haven Pharmaceuticals
  • Pfizer
  • RaQualia Pharma Inc
  • Renexxion LLC
  • Rottapharm
  • Takeda Pharmaceutical Co
  • Trio Medicines Ltd
  • Yooyoung Pharm Co Ltd
  • Yuyu Pharma Inc

4 Gastroesophageal Reflux Disease (GERD) R&D Pipeline Snapshots

  • Drug wise Pipeline Details
  • Therapeutic Candidate Name
  • Originator
  • Co-Developer/ License Partner
  • Orphan Drug Designation
  • Development Phase
  • Mechanism of Action
  • Current Status
  • Ongoing Clinical Trial Details

5 Recent Developments in Gastroesophageal Reflux Disease (GERD) Pipeline

6 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/fhcsm9/2018?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery, Gastrointestinal Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery, Gastrointestinal Drugs